Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies.

Hutchinson JM, Mesa KA, Alexander DL, Yu B, O'Rourke SM, Limoli KL, Wrin T, Deeks SG, Berman PW.

Front Immunol. 2019 May 15;10:1021. doi: 10.3389/fimmu.2019.01021. eCollection 2019.

2.

Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens.

Mesa KA, Yu B, Wrin T, Petropoulos CJ, Pogson GH, Alexander DL, Perez G, O'Rourke SM, Sinangil F, Robinson J, Conant MA, Berman PW.

PLoS One. 2019 Apr 10;14(4):e0213409. doi: 10.1371/journal.pone.0213409. eCollection 2019.

3.

HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.

Landais E, Murrell B, Briney B, Murrell S, Rantalainen K, Berndsen ZT, Ramos A, Wickramasinghe L, Smith ML, Eren K, de Val N, Wu M, Cappelletti A, Umotoy J, Lie Y, Wrin T, Algate P, Chan-Hui PY, Karita E; IAVI Protocol C Investigators; IAVI African HIV Research Network, Ward AB, Wilson IA, Burton DR, Smith D, Pond SLK, Poignard P.

Immunity. 2017 Nov 21;47(5):990-1003.e9. doi: 10.1016/j.immuni.2017.11.002.

4.

Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch.

MacLeod DT, Choi NM, Briney B, Garces F, Ver LS, Landais E, Murrell B, Wrin T, Kilembe W, Liang CH, Ramos A, Bian CB, Wickramasinghe L, Kong L, Eren K, Wu CY, Wong CH; IAVI Protocol C Investigators & The IAVI African HIV Research Network, Kosakovsky Pond SL, Wilson IA, Burton DR, Poignard P.

Immunity. 2016 May 17;44(5):1215-26. doi: 10.1016/j.immuni.2016.04.016.

5.

Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies.

Krumm SA, Mohammed H, Le KM, Crispin M, Wrin T, Poignard P, Burton DR, Doores KJ.

Retrovirology. 2016 Feb 2;13:8. doi: 10.1186/s12977-016-0241-5.

6.

Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort.

Landais E, Huang X, Havenar-Daughton C, Murrell B, Price MA, Wickramasinghe L, Ramos A, Bian CB, Simek M, Allen S, Karita E, Kilembe W, Lakhi S, Inambao M, Kamali A, Sanders EJ, Anzala O, Edward V, Bekker LG, Tang J, Gilmour J, Kosakovsky-Pond SL, Phung P, Wrin T, Crotty S, Godzik A, Poignard P.

PLoS Pathog. 2016 Jan 14;12(1):e1005369. doi: 10.1371/journal.ppat.1005369. eCollection 2016 Jan.

7.

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies.

McCoy LE, Falkowska E, Doores KJ, Le K, Sok D, van Gils MJ, Euler Z, Burger JA, Seaman MS, Sanders RW, Schuitemaker H, Poignard P, Wrin T, Burton DR.

PLoS Pathog. 2015 Aug 12;11(8):e1005110. doi: 10.1371/journal.ppat.1005110. eCollection 2015 Aug.

8.

Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses.

O'Rourke SM, Sutthent R, Phung P, Mesa KA, Frigon NL, To B, Horthongkham N, Limoli K, Wrin T, Berman PW.

PLoS One. 2015 Mar 20;10(3):e0119608. doi: 10.1371/journal.pone.0119608. eCollection 2015.

9.

Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.

Li JZ, Heisey A, Ahmed H, Wang H, Zheng L, Carrington M, Wrin T, Schooley RT, Lederman MM, Kuritzkes DR; ACTG A5197 Study Team.

AIDS. 2014 Nov 28;28(18):2649-57. doi: 10.1097/QAD.0000000000000478.

10.

Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice.

Stoddart CA, Galkina SA, Joshi P, Kosikova G, Long BR, Maidji E, Moreno ME, Rivera JM, Sanford UR, Sloan B, Cieplak W, Wrin T, Chan-Hui PY.

Virology. 2014 Aug;462-463:115-25. doi: 10.1016/j.virol.2014.05.036. Epub 2014 Jun 25.

11.

Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method.

Evans MC, Phung P, Paquet AC, Parikh A, Petropoulos CJ, Wrin T, Haddad M.

BMC Bioinformatics. 2014 Mar 19;15:77. doi: 10.1186/1471-2105-15-77.

12.

Correction: Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing Responses.

Yi G, Lapelosa M, Bradley R, Mariano TM, Dietz DE, Hughes S, Wrin T, Petropoulos C, Gallicchio E, Levy RM, Arnold E, Arnold GF.

PLoS One. 2013 Sep 27;8(9). doi: 10.1371/annotation/57fc0148-19fe-4b8b-b2f4-bb5f60baa971. eCollection 2013.

13.

Dynamics of viral evolution and neutralizing antibody response after HIV-1 superinfection.

Chaillon A, Wagner GA, Hepler NL, Little SJ, Kosakovsky Pond SL, Caballero G, Pacold ME, Phung P, Wrin T, Richman DD, Wertheim JO, Smith DM.

J Virol. 2013 Dec;87(23):12737-44. doi: 10.1128/JVI.02260-13. Epub 2013 Sep 18.

14.

Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses.

Yi G, Lapelosa M, Bradley R, Mariano TM, Dietz DE, Hughes S, Wrin T, Petropoulos C, Gallicchio E, Levy RM, Arnold E, Arnold GF.

PLoS One. 2013 Sep 6;8(9):e72205. doi: 10.1371/journal.pone.0072205. eCollection 2013.

15.

Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes.

Hoffenberg S, Powell R, Carpov A, Wagner D, Wilson A, Kosakovsky Pond S, Lindsay R, Arendt H, Destefano J, Phogat S, Poignard P, Fling SP, Simek M, Labranche C, Montefiori D, Wrin T, Phung P, Burton D, Koff W, King CR, Parks CL, Caulfield MJ.

J Virol. 2013 May;87(10):5372-83. doi: 10.1128/JVI.02827-12. Epub 2013 Mar 6.

16.

Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.

Narayan KM, Agrawal N, Du SX, Muranaka JE, Bauer K, Leaman DP, Phung P, Limoli K, Chen H, Boenig RI, Wrin T, Zwick MB, Whalen RG.

PLoS One. 2013;8(1):e52732. doi: 10.1371/journal.pone.0052732. Epub 2013 Jan 9.

17.

Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.

O'Rourke SM, Schweighardt B, Phung P, Mesa KA, Vollrath AL, Tatsuno GP, To B, Sinangil F, Limoli K, Wrin T, Berman PW.

J Virol. 2012 Nov;86(22):12105-14. doi: 10.1128/JVI.01352-12. Epub 2012 Aug 29.

18.

International network for comparison of HIV neutralization assays: the NeutNet report II.

Heyndrickx L, Heath A, Sheik-Khalil E, Alcami J, Bongertz V, Jansson M, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Ramaswamy M, Sattentau Q, Tolazzi M, Schuitemaker H, Willems B, Wrin T, Fenyö EM, Scarlatti G.

PLoS One. 2012;7(5):e36438. doi: 10.1371/journal.pone.0036438. Epub 2012 May 9.

19.

PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD, Wyatt RT, Mascola JR, Poignard P, Burton DR.

J Virol. 2012 Apr;86(8):4394-403. doi: 10.1128/JVI.06973-11. Epub 2012 Feb 15.

20.

Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.

Euler Z, van den Kerkhof TL, van Gils MJ, Burger JA, Edo-Matas D, Phung P, Wrin T, Schuitemaker H.

J Virol. 2012 Feb;86(4):2045-55. doi: 10.1128/JVI.06091-11. Epub 2011 Dec 7.

21.

Broad neutralization coverage of HIV by multiple highly potent antibodies.

Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD; Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P.

Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.

22.

Broad antibody mediated cross-neutralization and preclinical immunogenicity of new codon-optimized HIV-1 clade CRF02_AG and G primary isolates.

Agwale SM, Forbi JC, Notka F, Wrin T, Wild J, Wagner R, Wolf H.

PLoS One. 2011;6(8):e23233. doi: 10.1371/journal.pone.0023233. Epub 2011 Aug 4.

23.

A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein.

Du SX, Xu L, Zhang W, Tang S, Boenig RI, Chen H, Mariano EB, Zwick MB, Parren PW, Burton DR, Wrin T, Petropoulos CJ, Ballantyne JA, Chambers M, Whalen RG.

PLoS One. 2011;6(6):e20927. doi: 10.1371/journal.pone.0020927. Epub 2011 Jun 29.

24.

Combined antiretroviral therapy and immune pressure lead to in vivo HIV-1 recombination with ancestral viral genomes.

Buzón MJ, Wrin T, Codoñer FM, Dalmau J, Phung P, Bonjoch A, Coakley E, Clotet B, Martinez-Picado J.

J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):109-17. doi: 10.1097/QAI.0b013e318215ab0a.

PMID:
21372727
25.

Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies.

Smith DH, Winters-Digiacinto P, Mitiku M, O'Rourke S, Sinangil F, Wrin T, Montefiori DC, Berman PW.

PLoS One. 2010 Aug 11;5(8):e12076. doi: 10.1371/journal.pone.0012076.

26.

Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus.

O'Rourke SM, Schweighardt B, Phung P, Fonseca DP, Terry K, Wrin T, Sinangil F, Berman PW.

J Virol. 2010 Nov;84(21):11200-9. doi: 10.1128/JVI.00790-10. Epub 2010 Aug 11.

27.

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.

Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M, Berman PW, Self SG, Montefiori DC.

J Infect Dis. 2010 Aug 15;202(4):595-605. doi: 10.1086/654816.

28.

Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.

Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, Self S, Williams C, Gorny MK, Zolla-Pazner S.

PLoS One. 2010 Apr 21;5(4):e10254. doi: 10.1371/journal.pone.0010254.

29.

Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.

Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, Schuitemaker H.

J Infect Dis. 2010 Apr 1;201(7):1045-53. doi: 10.1086/651144.

PMID:
20170371
30.

Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors.

van Gils MJ, Bunnik EM, Burger JA, Jacob Y, Schweighardt B, Wrin T, Schuitemaker H.

J Virol. 2010 Apr;84(7):3576-85. doi: 10.1128/JVI.02622-09. Epub 2010 Jan 13.

31.

Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruption.

Schweighardt B, Wrin T, Meiklejohn DA, Spotts G, Petropoulos CJ, Nixon DF, Hecht FM.

J Acquir Immune Defic Syndr. 2010 Jan;53(1):36-46. doi: 10.1097/QAI.0b013e3181c4b885.

32.

Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.

Du SX, Idiart RJ, Mariano EB, Chen H, Jiang P, Xu L, Ostrow KM, Wrin T, Phung P, Binley JM, Petropoulos CJ, Ballantyne JA, Whalen RG.

Virology. 2009 Dec 5;395(1):33-44. doi: 10.1016/j.virol.2009.07.042. Epub 2009 Oct 8.

34.

Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.

van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H.

AIDS. 2009 Nov 27;23(18):2405-14. doi: 10.1097/QAD.0b013e32833243e7.

PMID:
19770692
35.

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW; Protocol G Principal Investigators, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR.

Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3.

36.

Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals.

Huang W, Toma J, Stawiski E, Fransen S, Wrin T, Parkin N, Whitcomb JM, Coakley E, Hecht FM, Deeks SG, Gandhi RT, Eshleman SH, Petropoulos CJ.

AIDS Res Hum Retroviruses. 2009 Aug;25(8):795-802. doi: 10.1089/aid.2008.0252.

37.

Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.

Zolla-Pazner S, Cohen S, Pinter A, Krachmarov C, Wrin T, Wang S, Lu S.

Virology. 2009 Sep 15;392(1):82-93. doi: 10.1016/j.virol.2009.05.039. Epub 2009 Jul 26.

38.

Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies.

O'Rourke SM, Schweighardt B, Scott WG, Wrin T, Fonseca DP, Sinangil F, Berman PW.

J Virol. 2009 Aug;83(15):7728-38. doi: 10.1128/JVI.00688-09. Epub 2009 May 27.

39.

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC.

J Virol. 2009 Jul;83(14):7337-48. doi: 10.1128/JVI.00110-09. Epub 2009 May 13.

40.

Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Arnold GF, Velasco PK, Holmes AK, Wrin T, Geisler SC, Phung P, Tian Y, Resnick DA, Ma X, Mariano TM, Petropoulos CJ, Taylor JW, Katinger H, Arnold E.

J Virol. 2009 May;83(10):5087-100. doi: 10.1128/JVI.00184-09. Epub 2009 Mar 11.

41.

International network for comparison of HIV neutralization assays: the NeutNet report.

Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcami J, Bongertz V, Jassoy C, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Sattentau Q, Schuitemaker H, Sutthent R, Wrin T, Scarlatti G.

PLoS One. 2009;4(2):e4505. doi: 10.1371/journal.pone.0004505. Epub 2009 Feb 20.

42.

Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.

Pantophlet R, Wrin T, Cavacini LA, Robinson JE, Burton DR.

Virology. 2008 Nov 25;381(2):251-60. doi: 10.1016/j.virol.2008.08.032. Epub 2008 Sep 26.

43.

Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD.

J Infect Dis. 2008 Feb 15;197(4):563-71. doi: 10.1086/526786.

PMID:
18275276
44.

Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection.

Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H, Boden D, Galovich J, Tenner-Racz K, Racz P, Carrington M, Petropoulos C, Katinger H, Markowitz M.

J Virol. 2007 Oct;81(20):11016-31. Epub 2007 Aug 8.

45.

Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals.

Schweighardt B, Liu Y, Huang W, Chappey C, Lie YS, Petropoulos CJ, Wrin T.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):1-11. Erratum in: J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):528.

PMID:
17514017
46.

Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR.

Virology. 2007 Aug 1;364(2):441-53. Epub 2007 Apr 6.

47.

Loss of HIV-1-specific T-cell responses associated with very rapid HIV-1 disease progression.

Streeck H, Schweighardt B, Jessen H, Allgaier RL, Wrin T, Stawiski EW, Jessen AB, Allen TM, Walker BD, Altfeld M.

AIDS. 2007 Apr 23;21(7):889-91. No abstract available.

PMID:
17415054
48.

Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies.

Kraft Z, Derby NR, McCaffrey RA, Niec R, Blay WM, Haigwood NL, Moysi E, Saunders CJ, Wrin T, Petropoulos CJ, McElrath MJ, Stamatatos L.

J Virol. 2007 Jun;81(12):6402-11. Epub 2007 Mar 28.

49.

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.

Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ.

Antimicrob Agents Chemother. 2007 Feb;51(2):566-75. Epub 2006 Nov 20.

50.

HIV evolution and escape.

Richman DD, Little SJ, Smith DM, Wrin T, Petropoulos C, Wong JK.

Trans Am Clin Climatol Assoc. 2004;115:289-303. Review.

Supplemental Content

Support Center